Pulmonary arterial hypertension

• Actelion

  Company1 trialPhase 3935 people

• Bial - Portela C S.A.

  Company1 trialPhase 126 people

• Rhode Island Hospital

  1 trialPhase 41 person

• National Heart, Lung, and Blood Institute

  1 trialPhase 3210 people

• Ain Shams University

  1 trialPhase 340 people

• Gustavo A Heresi, MD, MS

  1 trialPhase 278 people

• National Institutes of Health Clinical Center (CC)

  1 trialPhase 270 people

• Imperial College London

  1 trialPhase 256 people

National Heart, Lung, and Blood InstituteUS$2.6m4 grants since 2022

• Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension

  National Heart, Lung, and Blood InstituteVanderbilt University Medical CenterUS$716k2022–2027

• The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

  National Heart, Lung, and Blood InstituteVanderbilt University Medical CenterUS$755.3k2022–2027

• 1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

  National Heart, Lung, and Blood InstituteCleveland Clinic Lerner Com-cwruUS$814.8k2024–2030

• Master - 2/2 Empaglifozin To Improve Right Ventricular Function in Pulmonary Arterial Hypertension

  National Heart, Lung, and Blood InstituteCleveland Clinic Lerner Com-cwruUS$363.4k2024–2030